Anti-angiogenesis effect of the novel anti-inflammatory and pro-resolving lipid mediators

Investigative Ophthalmology and Visual Science

Volumn 50, Issue 10, 2009, Pages 4743-4752

  Jin, Yiping ^a   Arita, Makoto ^a   Zhang, Qiang ^a   Saban, Daniel R ^a   Chauhan, Sunil K ^a   Chiang, Nan ^a   Serhan, Charles N ^a   Dana, Reza ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; ASPIRIN TRIGGERED LIPOXIN A4 DERIVATIVE; BINDING PROTEIN; CD11B ANTIGEN; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; LIPOXIN RECEPTOR; MESSENGER RNA; RESOLVING D1; RESOLVING D1 RECEPTOR; RESOLVING E1; RESOLVING E1 RECEPTOR; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN A; VASCULOTROPIN C; VASCULOTROPIN RECEPTOR; VASCULOTROPIN RECEPTOR 2; 16 (4 FLUORO)PHENOXYLIPOXIN A4 METHYL ESTER; 16-(4-FLUORO)PHENOXYLIPOXIN A4 METHYL ESTER; 5S,12R,18R TRIHYDROXY 6Z,8E,10E,14Z,16E EICOSAPENTAENOIC ACID; 5S,12R,18R-TRIHYDROXY-6Z,8E,10E,14Z,16E-EICOSAPENTAENOIC ACID; CYTOKINE; DOCOSAHEXAENOIC ACID; DRUG DERIVATIVE; FORMYLPEPTIDE RECEPTOR; FPR1 PROTEIN, MOUSE; ICOSAPENTAENOIC ACID; LIPOXIN; RESOLVIN D1; VASCULAR ENDOTHELIAL GROWTH FACTOR A, MOUSE; VASCULAR ENDOTHELIAL GROWTH FACTOR C, MOUSE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CELL INFILTRATION; CONTROLLED STUDY; CORNEA CELL; CORNEA NEOVASCULARIZATION; DRUG POTENCY; EPITHELIUM; INNATE IMMUNITY; MACROPHAGE; MALE; MORPHOMETRICS; MOUSE; NEUTROPHIL CHEMOTAXIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; ANIMAL; BAGG ALBINO MOUSE; DISEASE MODEL; DOWN REGULATION; FLUORESCENT ANTIBODY TECHNIQUE; GENETICS; IMMUNOLOGY; METABOLISM; NEUTROPHIL; PHYSIOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ANGIOGENESIS INHIBITORS; ANIMALS; CORNEAL NEOVASCULARIZATION; CYTOKINES; DISEASE MODELS, ANIMAL; DOCOSAHEXAENOIC ACIDS; DOWN-REGULATION; EICOSAPENTAENOIC ACID; FLUORESCENT ANTIBODY TECHNIQUE, INDIRECT; LIPOXINS; MACROPHAGES; MALE; MICE; MICE, INBRED BALB C; NEUTROPHILS; RECEPTORS, FORMYL PEPTIDE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR C; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 70349577530     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.08-2462     Document Type: Article

References (42)

1. Edelman JL, Castro MR, Wen Y. Correlation of VEGF expression by leukocytes with the growth and regression of blood vessels in the rat cornea. Invest Ophthalmol Vis Sci. 1999;40:1112-1123.
2. Naldini A, Carraro F. Role of inflammatory mediators in angiogenesis. Curr Drug Targets Inflamm Allergy. 2005;4:3-8.
3. Benelli R, Morini M, Carrozzino F, et al. Neutrophils as a key cellular target for angiostatin: implications for regulation of angiogenesis and inflammation. FASEB J. 2002;16:267-269.
4. Sterescu AE, Rousseau-Harsany E, Farrell C, Powell J, David M, Dubois J. The potential efficacy of omega-3 fatty acids as antiangiogenic agents in benign vascular tumors of infancy. Med Hypotheses. 2006;66:1121-1124.
5. Serhan CN, Chiang N, Van Dyke TE. Resolving inflammation: dual anti-inflammatory and pro-resolution lipid mediators. Nat Rev Immunol. 2008;8:349-361.
6. Serhan CN, Clish CB, Brannon J, Colgan SP, Chiang N, Gronert K. Novel functional sets of lipid-derived mediators with antiinflammatory actions generated from omega-3 fatty acids via cyclooxygenase 2-nonsteroidal antiinflammatory drugs and transcellular processing. J Exp Med. 2003;192:1197-1204.
7. Serhan CN, Hong S, Gronert K, et al. Resolvins: a family of bioactive products of omega-3 fatty acid transformation circuits initiated by aspirin treatment that counter proinflammation signals. J Exp Med. 2002;196:1025-1037.
8. Brink C, Dahlén SE, Drazen J, et al. International Union of Pharmacology XXXVII: nomenclature for leukotriene and lipoxin receptors. Pharmacol Rev. 2003;55:195-222.
9. Munger KA, Montero A, Fukunaga M, et al. Transfection of rat kidney with human 15-lipoxygenase suppresses inflammation and preserves function in experimental glomerulonephritis. Proc Natl Acad Sci U S A. 1999;96:13375-13380.
10. Bandeira-Melo C, Bozza PT, Diaz BL, et al. Cutting edge: lipoxin (LX) A4 and aspirin-triggered 15-epi-LXA4 block allergen-induced eosinophil trafficking. J Immunol. 2002;164:2267-2271.
11. Levy BD, De Sanctis GT, Devchand PR, et al. Multi-pronged inhibition of airway hyper-responsiveness and inflammation by lipoxin A4. Nat Med. 2002;8:1018-1023.
12. Karp CL, Flick LM, Park KW, et al. Defective lipoxin-mediated anti-inflammatory activity in the cystic fibrosis airway. Nat Immunol. 2004;5:388-392.
13. Serhan CN, Jain A, Marleau S, et al. Reduced inflammation and tissue damage in transgenic rabbits overexpressing 15-lipoxygenase and endogenous anti-inflammatory lipid mediators. J Immunol. 2003;71:6856-6865.
14. Dana MR, Zhu SN, Yamada J. Topical modulation of interleukin-1 activity in corneal neovascularization. Cornea. 1998;17:403-409.
15. Dana MR, Streilein JW. Loss and restoration of immune privilege in eyes with corneal neovascularization. Invest Ophthalmol Vis Sci. 1996;37:2485-2494.
16. Williams CS, Tsujii M, Reese J, Dey SK, DuBois RN. Host cyclooxygenase-2 modulates carcinoma growth. J Clin Invest. 2005;105: 1589-1594.
17. Põld M, Zhu LX, Sharma S, et al. Cyclooxygenase-2-dependent expression of angiogenic CXC chemokines ENA-78/CXC ligand (CXCL) 5 and interleukin-8/CXCL8 in human non-small cell lung cancer. Cancer Res. 2004;64:1853-1860.
18. Arita M, Bianchini F, Aliberti J, et al. Stereochemical assignment, antiinflammatory properties, and receptor for the omega-3 lipid mediator resolvin E1. J Exp Med. 2005;201:713-722.
19. Sun YP, Oh SF, Uddin J, et al. Resolvin D1 and its aspirin-triggered 17R epimer: stereochemical assignments, anti-inflammatory properties, and enzymatic inactivation. J Biol Chem. 2007;282:9323-9334.
20. Serhan CN, Maddox JF, Petasis NA, et al. Design of lipoxin A4 stable analogs that block transmigration and adhesion of human neutrophils. Biochemistry. 1995;34:14609-14615.
21. Jin Y, Shen L, Chong EM, et al. The chemokine receptor CCR7 mediates corneal antigen-presenting cell trafficking. Mol Vis. 2007; 13:626-634.
22. Deshpande S, Zheng M, Lee S, et al. Bystander activation involving T lymphocytes in herpetic stromal keratitis. J Immunol. 2001;167: 2902-2910.
23. Biswas PS, Banerjee K, Zheng M, et al. Counteracting corneal immunoinflammatory lesion with interleukin-1 receptor antagonist protein. J Leukoc Biol. 2004;76:868-875.
24. Sonoda K, Sakamoto T, Yoshikawa H, et al. Inhibition of corneal inflammation by the topical use of Ras farnesyltransferase inhibitors: selective inhibition of macrophage localization. Invest Ophthalmol Vis Sci. 1998;39:2245-2251.
25. Serhan CN, Savill J. Resolution of inflammation: the beginning programs the end. Nat Immunol. 2005;12:1191-1197.
26. Schwab JM, Chiang N, Arita M, Serhan CN. Resolvin E1 and protectin D1 activate inflammation-resolution programmes. Nature. 2007;447:869-874.
27. Torisu H, Ono M, Kiryu H, et al. Macrophage infiltration correlates with tumor stage and angiogenesis in human malignant melanoma: possible involvement of TNFα and IL-1α. Int J Cancer. 2000;85: 182-188.
28. Ryuto M, Ono M, Izumi H, et al. Induction of vascular endothelial growth factor by tumor necrosis factor alpha in human glioma cells: possible roles of SP-1. J Biol Chem. 1996;271:28220-28228.
29. Yoshida S, Ono M, Shono T, et al. Involvement of interleukin-8, vascular endothelial growth factor, and basic fibroblast growth factor in tumor necrosis factor alpha-dependent angiogenesis. Mol Cell Biol. 1997;17:4015-4023.
30. Joukov V, Pajusola K, Kaipainen A, et al. A novel vascular endothelial growth factor, VEGF-C, is a ligand for the Flt4 (VEGFR-3) and KDR (VEGFR-2) receptor tyrosine kinases. EMBO J. 1996;15: 290-298.
31. Baldwin ME, Roufail S, Halford MM, Alitalo K, Stacker SA, Achen MG. Multiple forms of mouse vascular endothelial growth factor-D are generated by RNA splicing and proteolysis. J Biol Chem. 2001;276:44307-44414.
32. Fierro IM. Angiogenesis and lipoxins. Prostaglandins Leukot Essent Fatty Acids. 2005;73:271-275.
33. Connor KM, SanGiovanni JP, Lofqvist C, et al. Increased dietary intake of omega-3-polyunsaturated fatty acids reduces pathological retinal angiogenesis. Nat Med. 2007;13:868-873.
34. Nakao S, Kuwano T, Tsutsumi-Miyahara C, et al. Infiltration of COX-2-expressing macrophages is a prerequisite for IL-1 betainduced neovascularization and tumor growth. J Clin Invest. 2005; 115:2979-2991.
35. Fierro IM, Kutok JL, Serhan CN. Novel lipid mediator regulators of endothelial cell proliferation and migration: aspirin-triggered-15Rlipoxin A(4) and lipoxin A(4). J Pharmacol Exp Ther. 2002;300: 385-392.
36. Clish CB, O'Brien JA, Gronert K, Stahl GL, Petasis NA, Serhan CN. Local and systemic delivery of a stable aspirin-triggered lipoxin prevents neutrophil recruitment in vivo. Proc Natl Acad Sci U S A. 1999;96:8247-8252.
37. Chiang N, Serhan CN, Dahlen SE, et al. The lipoxin receptor ALX: potent ligand-specific and stereoselective actions in vivo. Pharmacol Rev. 2006;58:463-487.
38. Cezar-de-Mello PF, Nascimento-Silva V, Villela CG, Fierro IM. Aspirin- triggered lipoxin A4 inhibition of VEGF-induced endothelial cell migration involves actin polymerization and focal adhesion assembly. Oncogene. 2006;25:122-129.
39. Cezar-de-Mello PF, Vieira AM, Nascimento-Silva V, Villela CG, Barja- Fidalgo C, Fierro IM. ATL-1, an analogue of aspirin-triggered lipoxin A(4), is a potent inhibitor of several steps in angiogenesis induced by vascular endothelial growth factor. Br J Pharmacol. 2008;153:956-965.
40. Wittamer V, Franssen JD, Vulcano M, et al. Specific recruitment of antigen-presenting cells by chemerin, a novel processed ligand from human inflammatory fluids. J Exp Med. 2003;198:977-985.
41. Gronert K, Gewirtz A, Madara JL, Serhan CN. Identification of a human enterocyte lipoxin A4 receptor that is regulated by interleukin (IL)-13 and interferon gamma and inhibits tumor necrosis factor alpha-induced IL-8 release. J Exp Med. 1998;187: 1285-1294.
42. Gronert K, Maheshwari N, Khan N, Hassan IR, Dunn M, Laniado Schwartzman M. A role for the mouse 12/15-lipoxygenase pathway in promoting epithelial wound healing and host defense. J Biol Chem. 2005;280:15267-15278.